Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Home
/
update
/
details

Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NextEdge Admin

10 Jan 2025

2 min 13 sec

Kotak Strategic Situations India Fund II, managed by Kotak Alternate Asset Managers, has invested ₹940 crore in Neuberg Diagnostics to support its expansion strategy. This investment aims to accelerate Neuberg’s inorganic growth and strengthen its market position in India’s diagnostic sector.

Founded by industry veteran GSK Velu, Neuberg has grown into a key player with over 10,000 touchpoints and 250 labs across 250 cities. The company holds a strong market presence in Gujarat and Karnataka and has positioned itself as the second-largest genomics provider in India. It is particularly recognized for its expertise in newborn screening and reproductive genomics testing.

Rahul Shah, Partner at Kotak Alt, emphasized that the investment reflects confidence in Neuberg’s growth trajectory. He stated that the funds would help the company scale operations and prepare for an initial public offering (IPO).

GSK Velu, Founder and MD of Neuberg, highlighted that the investment would enhance the company’s capabilities in personalized medicine and integrated diagnostics. He also noted that it would support inorganic growth across India, furthering Neuberg’s mission of expanding high-quality diagnostic services.

“As we prepare for an IPO, we remain committed to making diagnostics more accessible and improving healthcare outcomes,” Velu said.

With this investment, Neuberg aims to solidify its leadership in the diagnostics and genomics space while expanding its footprint and service offerings in India’s evolving healthcare landscape.